ProCE Banner Activity

Key Challenges in Managing Patients With CLL

Clinical Thought

Expert discussion of areas of unmet need in treating patients with CLL, including individualizing frontline therapy and treating relapsed/refractory disease and Richter’s transformation.

Released: November 15, 2023

Expiration: November 14, 2024

Share

Faculty

Danielle M. Brander

Danielle M. Brander, MD

Assistant Professor of Medicine
Division of Hematologic Malignancies and Cellular Therapy
Duke Cancer Institute
Durham, North Carolina

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in partnership with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, BeiGene and Lilly.

AstraZeneca

BeiGene

Lilly

Partners

Clinical Care Options, LLC

ProCE Banner

Disclosure

Primary Author

Danielle M. Brander, MD

Assistant Professor of Medicine
Division of Hematologic Malignancies and Cellular Therapy
Duke Cancer Institute
Durham, North Carolina

Danielle Brander, MD: consultant/advisor/speaker: AbbVie, ArQule/Merck, Genentech, Pfizer, Pharmacyclics, TG Therapeutics; researcher: AbbVie, AstraZeneca, ArQule/Merck, Beigene, CATO SMS, DTRM, Genentech, Juno/Celgene/Bristol Myers Squibb, Newave, Pfizer, Pharmacyclics, TG Therapeutics.